Xiamen Amoytop Biotech Co., Ltd. (SHA:688278)
China
· Delayed Price · Currency is CNY 59.35
+0.50 (0.85%)
Apr 29, 2026, 3:00 PM CST
Xiamen Amoytop Biotech Revenue
Xiamen Amoytop Biotech had revenue of 797.79M CNY in the quarter ending March 31, 2026, with 18.48% growth. This brings the company's revenue in the last twelve months to 3.82B, up 29.70% year-over-year. In the year 2025, Xiamen Amoytop Biotech had annual revenue of 3.70B with 31.18% growth.
Revenue (ttm)
3.82B
Revenue Growth
+29.70%
P/S Ratio
6.50
Revenue / Employee
1.01M
Employees
3,644
Market Cap
24.02B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 3.70B | 878.41M | 31.18% |
| Dec 31, 2024 | 2.82B | 716.84M | 34.13% |
| Dec 31, 2023 | 2.10B | 573.42M | 37.55% |
| Dec 31, 2022 | 1.53B | 394.68M | 34.86% |
| Dec 31, 2021 | 1.13B | 338.29M | 42.61% |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Yili Chuanning Biotechnology | 4.41B |
| BrightGene Bio-Medical Technology | 1.22B |
| Hualan Biological Engineering | 4.49B |
| Suzhou Zelgen Biopharmaceuticals | 810.48M |
| Beijing Tiantan Biological Products | 6.17B |
| Sinocelltech Group | 1.56B |
| Mabwell (Shanghai) Bioscience | 662.52M |
| Chongqing Zhifei Biological Products | 10.91B |